MX2022009383A - Usos terapéuticos de dulaglutida. - Google Patents
Usos terapéuticos de dulaglutida.Info
- Publication number
- MX2022009383A MX2022009383A MX2022009383A MX2022009383A MX2022009383A MX 2022009383 A MX2022009383 A MX 2022009383A MX 2022009383 A MX2022009383 A MX 2022009383A MX 2022009383 A MX2022009383 A MX 2022009383A MX 2022009383 A MX2022009383 A MX 2022009383A
- Authority
- MX
- Mexico
- Prior art keywords
- patient
- dulaglutide
- effective amount
- methods
- therapeutically effective
- Prior art date
Links
- 229960005175 dulaglutide Drugs 0.000 title abstract 3
- 108010005794 dulaglutide Proteins 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 abstract 3
- 230000006999 cognitive decline Effects 0.000 abstract 2
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002641 glycemic effect Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 230000003442 weekly effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a métodos para tratar, prevenir o retrasar trastornos relacionados con la cognición, como el deterioro cognitivo, la deficiencia cognitiva o la demencia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062967790P | 2020-01-30 | 2020-01-30 | |
| PCT/US2021/014525 WO2021154591A1 (en) | 2020-01-30 | 2021-01-22 | Therapeutic uses of dulaglutide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009383A true MX2022009383A (es) | 2022-11-07 |
Family
ID=77078331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009383A MX2022009383A (es) | 2020-01-30 | 2021-01-22 | Usos terapéuticos de dulaglutida. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230088005A1 (es) |
| EP (1) | EP4096704A4 (es) |
| JP (1) | JP2023513054A (es) |
| KR (1) | KR20220132606A (es) |
| CN (1) | CN114980917A (es) |
| AU (1) | AU2021213682A1 (es) |
| BR (1) | BR112022014862A2 (es) |
| CA (1) | CA3166573A1 (es) |
| IL (1) | IL295182A (es) |
| MX (1) | MX2022009383A (es) |
| WO (1) | WO2021154591A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190142905A1 (en) * | 2016-04-19 | 2019-05-16 | Ureka Sarl | Peptide-oligourea foldamer compounds and methods of their use |
| KR102589234B1 (ko) * | 2017-11-21 | 2023-10-16 | 일라이 릴리 앤드 캄파니 | 둘라글루티드를 함유하는 조성물 및 사용 방법 |
| BR112022007721A2 (pt) * | 2019-11-06 | 2022-07-12 | Novo Nordisk As | Método para o tratamento da demência |
-
2021
- 2021-01-22 KR KR1020227029410A patent/KR20220132606A/ko unknown
- 2021-01-22 CA CA3166573A patent/CA3166573A1/en active Pending
- 2021-01-22 CN CN202180012202.6A patent/CN114980917A/zh active Pending
- 2021-01-22 EP EP21748329.6A patent/EP4096704A4/en active Pending
- 2021-01-22 MX MX2022009383A patent/MX2022009383A/es unknown
- 2021-01-22 AU AU2021213682A patent/AU2021213682A1/en active Pending
- 2021-01-22 IL IL295182A patent/IL295182A/en unknown
- 2021-01-22 WO PCT/US2021/014525 patent/WO2021154591A1/en active Application Filing
- 2021-01-22 JP JP2022546514A patent/JP2023513054A/ja active Pending
- 2021-01-22 US US17/795,797 patent/US20230088005A1/en active Pending
- 2021-01-22 BR BR112022014862A patent/BR112022014862A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023513054A (ja) | 2023-03-30 |
| WO2021154591A1 (en) | 2021-08-05 |
| IL295182A (en) | 2022-09-01 |
| EP4096704A1 (en) | 2022-12-07 |
| KR20220132606A (ko) | 2022-09-30 |
| EP4096704A4 (en) | 2024-01-31 |
| CN114980917A (zh) | 2022-08-30 |
| AU2021213682A1 (en) | 2022-08-25 |
| BR112022014862A2 (pt) | 2022-10-11 |
| US20230088005A1 (en) | 2023-03-23 |
| CA3166573A1 (en) | 2021-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004052284A3 (en) | Treatment of diabetes | |
| WO2009035534A3 (en) | Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) | |
| WO2006071548A3 (en) | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases | |
| MX2022015613A (es) | Composiciones de benzofurano beneficiosas para trastornos mentales o mejoramiento mental. | |
| WO2003092584A3 (en) | Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies | |
| WO2010057020A3 (en) | Modification of amyloid-beta load in non-brain tissue | |
| MX2009006768A (es) | Metodos, compuestos, y composiciones para tratar trastornos metabolicos y diabetes. | |
| MX2022009384A (es) | Usos terapeuticos de la tirzepatida. | |
| EP4233913A3 (en) | Improved bromocriptine formulations | |
| MX2022009383A (es) | Usos terapéuticos de dulaglutida. | |
| IL186356A0 (en) | Method of treating of preventing type-2 diabetes | |
| WO2022081610A8 (en) | TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR | |
| WO2009131850A3 (en) | Pai-1 expression and activity inhibitors for the treatment of ocular disorders | |
| Lin | Acupuncture for persistent hiccups in a heart and lung transplant recipient | |
| WO2003030836A3 (en) | Neuronal regeneration | |
| Fenner et al. | Sublingual glyceryl trinitrate as prehospital treatment for hypertension in Irukandji syndrome | |
| WO2022177742A3 (en) | Tirzepatide therapeutic methods | |
| MX2023003258A (es) | Tratamiento de enfermedades mediadas por nf-kb. | |
| EP1152760A4 (en) | USE OF 4-AMINO PYRIDINE FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES | |
| MX2021010683A (es) | Esketamina para el tratamiento de la depresión. | |
| WO2005094282A3 (en) | Combination therapy comprising cloretazinetm | |
| WO2005097102A3 (en) | Method to treat chronic heart failure and/or elevated cholesterol levels | |
| NL2025716B1 (en) | Use of phenol in treatment of systemic oxidative stress mediated diseases | |
| MX2022011129A (es) | Composicion farmaceutica para la prevencion o el tratamiento de la diabetes y de enfermedades metabolicas asociadas a la misma. | |
| EP4245366A3 (en) | Migalastat for treating fabry patients having renal impairment |